These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 16961727)

  • 1. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors.
    Imig JD
    Cardiovasc Drug Rev; 2006; 24(2):169-88. PubMed ID: 16961727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
    Revermann M
    Curr Opin Pharmacol; 2010 Apr; 10(2):173-8. PubMed ID: 20079692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.
    Ni GH; Chen JF; Chen XP; Yang TL
    Pharmazie; 2011 Mar; 66(3):153-7. PubMed ID: 21553642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
    Zhao X; Yamamoto T; Newman JW; Kim IH; Watanabe T; Hammock BD; Stewart J; Pollock JS; Pollock DM; Imig JD
    J Am Soc Nephrol; 2004 May; 15(5):1244-53. PubMed ID: 15100364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble epoxide hydrolase inhibitors and cardiovascular diseases.
    Wang ZH; Davis BB; Jiang DQ; Zhao TT; Xu DY
    Curr Vasc Pharmacol; 2013 Jan; 11(1):105-11. PubMed ID: 22303912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.
    Imig JD; Hammock BD
    Nat Rev Drug Discov; 2009 Oct; 8(10):794-805. PubMed ID: 19794443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble epoxide hydrolase inhibitors: a patent review.
    Shen HC
    Expert Opin Ther Pat; 2010 Jul; 20(7):941-56. PubMed ID: 20429668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery.
    Marino JP
    Curr Top Med Chem; 2009; 9(5):452-63. PubMed ID: 19519461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of soluble epoxide hydrolase by extracts derived from inflammation-treating Chinese medicinal herbs.
    Shi DH; Xu C; Guo BX; Wang XT; Chen YX; Tan RX
    Phytother Res; 2008 Sep; 22(9):1264-8. PubMed ID: 18729246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis.
    Enayetallah AE; Grant DF
    Biochem Biophys Res Commun; 2006 Mar; 341(1):254-60. PubMed ID: 16414022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility.
    Kim IH; Morisseau C; Watanabe T; Hammock BD
    J Med Chem; 2004 Apr; 47(8):2110-22. PubMed ID: 15056008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The soluble epoxide hydrolase as a pharmaceutical target for hypertension.
    Chiamvimonvat N; Ho CM; Tsai HJ; Hammock BD
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):225-37. PubMed ID: 17878749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble epoxide hydrolase: a novel target for the treatment of hypertension.
    Fang X
    Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):67-72. PubMed ID: 18221075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.
    Eldrup AB; Soleymanzadeh F; Taylor SJ; Muegge I; Farrow NA; Joseph D; McKellop K; Man CC; Kukulka A; De Lombaert S
    J Med Chem; 2009 Oct; 52(19):5880-95. PubMed ID: 19746975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N'-diaryl urea inhibitors of soluble epoxide hydrolase.
    Anandan SK; Gless RD
    Bioorg Med Chem Lett; 2010 May; 20(9):2740-4. PubMed ID: 20363133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.
    Eldrup AB; Soleymanzadeh F; Farrow NA; Kukulka A; De Lombaert S
    Bioorg Med Chem Lett; 2010 Jan; 20(2):571-5. PubMed ID: 19969453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase.
    Taylor SJ; Soleymanzadeh F; Eldrup AB; Farrow NA; Muegge I; Kukulka A; Kabcenell AK; De Lombaert S
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5864-8. PubMed ID: 19758802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble epoxide hydrolase inhibitors and heart failure.
    Qiu H; Li N; Liu JY; Harris TR; Hammock BD; Chiamvimonvat N
    Cardiovasc Ther; 2011 Apr; 29(2):99-111. PubMed ID: 20433684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-specific subcellular localization of soluble epoxide hydrolase in human tissues.
    Enayetallah AE; French RA; Barber M; Grant DF
    J Histochem Cytochem; 2006 Mar; 54(3):329-35. PubMed ID: 16314446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450-dependent eicosanoid production and crosstalk.
    Fleming I
    Curr Opin Lipidol; 2011 Oct; 22(5):403-9. PubMed ID: 21825980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.